WAT

<span> <style type="text/css"> //<![CDATA[ .q4default span.prnews_span { font-size: 8pt; font-family: "Arial"; color: rgb(0, 0, 0) } .q4default a.prnews_a { color: rgb(0, 0, 255) } .q4default li.prnews_li { font-size: 8pt; font-family: "Arial"; color: rgb(0, 0, 0) } .q4default p.prnews_p { font-size: 0.62em; font-family: "Arial"; color: rgb(0, 0, 0); margin: 0 } //]]>// </style> <div class="q4default"> <div class="xn-content"> <ul type="disc"><li>IMU's AI platform unlocks unprecedented immune insights for cancer and other diseases, measuring 100M+ data points from a single blood sample, analyzed in real time.</li><li>Waters Biosciences' technologies, including BD FACSDiscover™ and BD Rhapsody™ Instruments, will be used with IMU's AI analytics in research to deliver deeper, population-level disease insights.</li><li>Partnership supports IMU's expansion of its world-leading immune dataset through large-scale studies, establishing a new standard for immune profiling.</li></ul><p><span class="legendSpanClass">MILFORD, Mass.</span>, <span class="legendSpanClass">June 24, 2026</span> /PRNewswire/ -- Waters Corporation (NYSE: WAT) and IMU Biosciences, a biotechnology company decoding the immune system to pioneer a paradigm shift in how we understand, diagnose, and treat disease, today announced a strategic partnership to accelerate the development of IMU's next-generation AI-powered High Definition (HD) Immunology platform.</p><p>The partnership brings together Waters Biosciences' advanced flow cytometry and single-cell technologies,¹ including BD FACSDiscover Cell Analyzers, BD flow cytometry reagents with BD Horizon™ Real Dyes, BD Rhapsody Instruments, and BD OMICS-One™ WTA Next Assay and Protein Panels, with IMU's HD analysis and proprietary AI and machine learning analytics, that can reproducibly characterize the immune system in real time, to turn complex immune data into insights at scale across discovery, translational, and clinical research applications.</p><p>IMU measures the immune system in unprecedented detail, delivering more than 100 million data points from a single blood sample,² combining HD multiomic analysis with machine learning analytics. IMU is building the world's largest immune dataset,³ with unrivaled access to patient samples and population-wide clinical data, establishing a universal standard for immune profiling.</p><p>"Waters Biosciences was the clear partner to help IMU Biosciences scale our HD Immunology platform to the level required for true population-wide immune mapping, given their longstanding leadership in high-throughput flow cytometry and single-cell technologies," said John Baker, Ph.D., Chief Executive Officer, IMU Biosciences. "Our world-leading immune dataset and proprietary AI analytics will unlock the potential of Waters' best-in-class analytical instruments, accelerating our work to decode the immune system and power the next generation of precision medicine."</p><p>Steve Conly, Senior Vice President, Waters Biosciences, Waters Corporation added, "By partnering with IMU Biosciences, we are helping to build the most detailed picture of the human immune system ever assembled at clinical scale. Together, our companies' cutting-edge technologies across instruments, reagents, and informatics will help advance immune profiling into a standardized, universally accessible clinical tool that can be used across the continuum of care for cancer and other diseases, supporting smarter, faster drug development."</p><p>The companies intend to pursue additional studies in translational research for novel biomarker discovery to enable clinical applications in flow cytometry. Waters Biosciences and IMU Biosciences presented data at the annual meeting of the International Society for the Advancement of Cytometry (CYTO 2026), demonstrating system-level immune profiling on the BD FACSDiscover A8 Cell Analyzer with a 58-color spectral panel using BD reagents, and i

<span> <style type="text/css"> //<![CDATA[ .q4default span.prnews_span { font-size: 8pt; font-family: "Arial"; color: rgb(0, 0, 0) } .q4default a.prnews_a { color: rgb(0, 0, 255) } .q4default li.prnews_li { font-size: 8pt; font-family: "Arial"; color: rgb(0, 0, 0) } .q4default p.prnews_p { font-size: 0.62em; font-family: "Arial"; color: rgb(0, 0, 0); margin: 0 } //]]>// </style> <div class="q4default"> <div class="xn-content"> <ul type="disc"><li>Integrates heat flow, evolved gas, and electrochemical analysis in a single experiment, enabling earlier insights into thermal runaway.</li><li>Unique whole-cell design eliminates cell teardown, reducing sample preparation time by >90%.</li><li>Industry-leading Coin Cell DSC temperature range from –80 °C to 600 °C, aiding battery development and QA/QC.</li></ul><p><span class="legendSpanClass">MILFORD, Mass.</span>, <span class="legendSpanClass">June 9, 2026</span> /PRNewswire/ -- Waters Corporation (NYSE: WAT) today announced the launch of the Waters TA Instruments™ Coin Cell Differential Scanning Calorimeter (DSC), designed to transform battery safety testing. Purpose-built for battery scientists, the Coin Cell DSC enables direct testing of fully assembled coin cells, eliminating time-intensive preparation steps while delivering faster, more descriptive safety and performance insights.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1858939/TAinst-CoinCellDSC-2-EGA-PR_-1.jpg?id=OA2690343" title="Waters TA Instruments Coin Cell Differential Scanning Calorimeter advances battery safety, delivering integrated heat flow, evolved gas, and electrochemical analysis in a single experiment." alt="Waters TA Instruments Coin Cell Differential Scanning Calorimeter advances battery safety, delivering integrated heat flow, evolved gas, and electrochemical analysis in a single experiment." /> </p> </div> <p>The Coin Cell DSC is the only commercially available DSC¹ that provides multidimensional data capture and enables researchers to collect whole-cell thermal data while simultaneously measuring evolved gas and electrochemical performance. By incorporating voltage monitoring and charge/discharge capability, researchers can directly correlate thermal and electrochemical behavior enabling earlier insights into thermal runaway and battery failure. It can also be coupled with MS, Fourier Transform Infrared Spectroscopy (FTIR), or Gas Chromatography-Mass Spectrometry (GC-MS) to enable direct analysis of off-gas composition.</p><p>"The Coin Cell DSC represents a significant advancement in battery thermal analysis," said Yu Cheng, Vice President, Research and Development and Product Solutions, Materials Sciences, Waters Corporation. "Simultaneously capturing thermal, evolved gas, and electrochemical data is not only faster, but also correlates data from the same sample for more exacting insights earlier in development. With its broad temperature range and streamlined workflows, the system is designed to reduce experimental complexity while outperforming current approaches."</p><p>The Coin Cell DSC introduces a unique capsule design that eliminates the highly time-consuming need for cell teardown, reducing the average sample preparation time by more than 90%.² This approach preserves sample integrity while significantly accelerating data generation.</p><p>The new system redefines thermal analysis by integrating advanced temperature performance, efficient workflows, and multidimensional data capture into a single platform. With an industry-leading –80 °C to 600 °C range,^{3, 4} the Coin Cell DSC enables comprehensive analysis of low- and high-temperature behavior, expanding future applications in development and QA/QC.</p><p>"The battery industry has long needed a solution that bridges the gap between materials thermal analysis and ful

<span> <style type="text/css"> //<![CDATA[ .q4default span.prnews_span { font-size: 8pt; font-family: "Arial"; color: rgb(0, 0, 0) } .q4default a.prnews_a { color: rgb(0, 0, 255) } .q4default li.prnews_li { font-size: 8pt; font-family: "Arial"; color: rgb(0, 0, 0) } .q4default p.prnews_p { font-size: 0.62em; font-family: "Arial"; color: rgb(0, 0, 0); margin: 0 } //]]>// </style> <div class="q4default"> <div class="xn-content"> <ul type="disc"><li>Faster run times for <span>GLP-1</span>, insulin, and LNP drug substance testing accelerates biopharmaceutical development timelines and reduces production bottlenecks.</li><li>Delivers up to 2x increase in resolving power and sensitivity to identify and track low-level impurities for improved regulatory readiness.</li><li>Industry-first chemical and physical particle optimization delivers reproducible methods for increasingly complex biologics.</li></ul><p><span class="legendSpanClass">MILFORD, Mass.</span>, <span class="legendSpanClass">June 8, 2026</span> /PRNewswire/ -- 55th International Symposium on High Performance Liquid Phase Separations and Related Techniques—Waters Corporation (NYSE: WAT) today announced the launch of the BioResolve™ Peptide and GTxResolve™ Lipid Phenyl-Hexyl+ and C18+ Columns, a first-of-its-kind reversed-phase (RP) column platform designed to tackle a persistent biopharmaceutical challenge: reliably separating structurally and chemically similar impurities in <span>GLP-1</span> peptides, insulin, and lipid nanoparticles (LNPs) to support the development of safe, effective drug products.</p><div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder2433"><p><img src="https://mmx.prnewswire.com/media/MS1858794/Press_Release_RP230_Graphic.jpg?id=OA2690047" title="BioResolve Peptide and GTxResolve Lipid Columns are the first columns Waters has introduced to market specifically QC batch-tested for GLP-1 analysis and lipid nanoparticles, solving a longstanding customer pain point." alt="BioResolve Peptide and GTxResolve Lipid Columns are the first columns Waters has introduced to market specifically QC batch-tested for GLP-1 analysis and lipid nanoparticles, solving a longstanding customer pain point." /></p></div><div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder8483"><p><img src="https://mmx.prnewswire.com/media/MS636097/Waters_Corporation_Logo.jpg?id=OA2690046" title="(PRNewsfoto/Waters Corporation)" alt="(PRNewsfoto/Waters Corporation)" /></p></div><p>In <span>GLP-1</span> receptor agonists and newer mRNA-based therapies such as in vivo CAR T, difficulty resolving impurities can delay time to market, weaken regulatory confidence, and affect patient safety. Traditional RP columns do not always separate low-level or closely related impurities well, often requiring longer analyses, detector-suppressing mobile-phase additives, or repeated method redevelopment. BioResolve Peptide and GTxResolve Lipid Columns help to overcome these limitations with ready-to-use methods that improve both resolution^1,2and speed^2,3 while fitting into existing workflows.</p><p>"We have made simultaneous advances in both chemistry and particle physics to deliver the first columns Waters has introduced to market specifically QC batch-tested for GLP‑1 analysis⁴ and lipid nanoparticles,² solving a longstanding customer pain point," said Erin Chambers, Vice President, General Manager, Consumables & Lab Automation, Waters Analytical Sciences, Waters Corporation. "BioResolve Peptide and GTxResolve Lipid Columns are designed to resolve chemically similar GLP‑1 impurities and LNP components faster when speed matters,^2,3 and with extraordinary resolution¹ when certainty is required. The result is simpler method development, regulatory‑ready data,⁵ and faster, highly reproducible methods, ultimately helping to reduce cost burdens on important new therapeutics."</p><p>BioResolve Peptide and

<span> <style type="text/css"> //<![CDATA[ .q4default span.prnews_span { font-size: 8pt; font-family: "Arial"; color: rgb(0, 0, 0) } .q4default a.prnews_a { color: rgb(0, 0, 255) } .q4default li.prnews_li { font-size: 8pt; font-family: "Arial"; color: rgb(0, 0, 0) } .q4default p.prnews_p { font-size: 0.62em; font-family: "Arial"; color: rgb(0, 0, 0); margin: 0 } //]]>// </style> <div class="q4default"> <div class="xn-content"> <ul type="disc"><li>FDA 510(k)-cleared BD BACTEC™ FXI Culture System now available to U.S. market, enabling broader access to confident bloodstream infection diagnostics.</li><li>Achieves a 3-hour faster time to detection (~15% reduction) versus the prior-generation system, per clinical study data, enabling earlier targeted sepsis prevention.</li><li>Fully automated solution delivers an industry-leading 50% increase in vial loading and up to 960-vial per module capacity, maximizing walk-away time.</li></ul><p><span class="legendSpanClass">MILFORD, Mass.</span>, <span class="legendSpanClass">June 3, 2026</span> /PRNewswire/ -- Waters Corporation (NYSE: WAT) today announced that the BD BACTEC FXI Culture System has received U.S. Food and Drug Administration (FDA) 510(k) clearance. This clearance enables commercialization in the U.S. and provides a new option for laboratories seeking a fully automated blood culture system designed to improve the speed, consistency, and accuracy of sepsis and bloodstream infection diagnostics in modern microbiology laboratories.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <a href="https://mma.prnewswire.com/media/2993851/BD_BACTEC_FXI_A__Waters_Corporation.html" target="_blank" rel="nofollow"> <img src="https://mma.prnewswire.com/media/2993851/BD_BACTEC_FXI_A__Waters_Corporation.jpg" title="FDA 510(k)-cleared BD BACTEC FXI Culture System now available to U.S. market, enabling broader access to confident bloodstream infection diagnostics." alt="FDA 510(k)-cleared BD BACTEC FXI Culture System now available to U.S. market, enabling broader access to confident bloodstream infection diagnostics." /> </a> </p> </div> <p>Clinical study data¹ showed that the BD BACTEC FXI Culture System reduced mean time to detection by approximately three hours (~15%) compared with the previous-generation BD BACTEC™ FX Blood Culture System (17 hours vs. 20 hours). Faster detection enables earlier pathogen identification and more timely targeted antimicrobial therapy for patients with suspected bloodstream infections and sepsis. Because each hour of delayed sepsis treatment increases mortality by 3.6% to 9.9%,² faster diagnostic workflows are critical in acute care settings.</p><p>"Recent evidence-based laboratory guidelines document the beneficial clinical impact of rapid laboratory results for the detection of bloodstream infections; therefore, advancing the science of automated blood culture instruments is critical to further speed results," said Donna M. Wolk, MHA, Ph.D., D(ABMM), Division Chief, Molecular and Microbial Diagnostics and Development, Geisinger Medical Laboratories. "Reducing the time to detection for positive results is key to improving the availability of Gram stain and other tests, on which treatment decisions are based. The faster, the better."</p><p>The BD BACTEC FXI Culture System features a first-of-its-kind capability in a blood culture platform – an automated gravimetric measurement of individual blood culture vial volume. By objectively confirming blood volume in each vial, the system reduces pre-analytical variability and supports more consistent diagnostics and adherence to recommended collection practices.</p><p>"Waters is proud to bring the BD BACTEC FXI Culture System to the U.S. market, delivering an important advancement in bloodstream infection diagnostics," said Jianqing Bennett, Senior Vice President, W

<span> <style type="text/css"> //<![CDATA[ .q4default span.prnews_span { font-size: 8pt; font-family: "Arial"; color: rgb(0, 0, 0) } .q4default a.prnews_a { color: rgb(0, 0, 255) } .q4default li.prnews_li { font-size: 8pt; font-family: "Arial"; color: rgb(0, 0, 0) } .q4default p.prnews_p { font-size: 0.62em; font-family: "Arial"; color: rgb(0, 0, 0); margin: 0 } //]]>// </style> <div class="q4default"> <div class="xn-content"> <ul type="disc"><li>>10x step-change in MS/MS sensitivity paired with multipass Cyclic™ Ion Mobility Spectrometry (IMS) reveals subtle biological differences for earlier, previously unattainable detection of disease signals.</li></ul><ul type="disc"><li>50% extended upper mass range and comprehensive suite of structural tools advance the development of next-generation biotherapeutics.</li></ul><ul type="disc"><li>Integrated MALDI XS and DESI XS imaging with high-resolution ion mobility enables direct visualization of molecules in tissue, improving understanding of how disease develops at the cellular level.</li></ul><p><span class="legendSpanClass">MILFORD, Mass.</span>, <span class="legendSpanClass">June 1, 2026</span> /PRNewswire/ -- 74^th ASMS Conference on Mass Spectrometry and Allied Topics— Waters Corporation (NYSE: WAT) today announced the launch of the <a href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4700516-1&h=966744027&u=https%3A%2F%2Fwww.waters.com%2Fnextgen%2Fus%2Fen%2Fproducts%2Fmass-spectrometry%2Fmass-spectrometry-systems%2FcyclicIMSP20.html%3Fcontp-npd_35453&a=Waters+Cyclic+IMS+P20+Mass+Spectrometer" target="_blank" rel="nofollow">Waters Cyclic IMS P20 Mass Spectrometer</a>, a high-resolution structural and spatial omics platform designed to help scientists see biology more clearly, and act on it faster. Combining multipass Cyclic Ion Mobility Spectrometry with an enhanced suite of fragmentation, probing, and imaging capabilities<b>, </b>this unique and powerful instrument delivers confident insights for the early detection of disease signals, from protein misfolding to post-translational modifications. The system's full‑spectrum molecular imaging unlocks unparalleled visualization within a single experiment¹ to accelerate discovery and development, and power deeper understanding of complex biology.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <a href="https://mma.prnewswire.com/media/2991658/Waters_Cyclic_IMS_P20.html" target="_blank" rel="nofollow"> <img src="https://mma.prnewswire.com/media/2991658/Waters_Cyclic_IMS_P20.jpg" title="Combining multipass Cyclic Ion Mobility Spectrometry with an enhanced suite of fragmentation, probing, and imaging capabilities, the Waters Cyclic IMS P20 Mass Spectrometer reveals subtle biological differences for earlier, previously unattainable detection of disease signals." alt="Combining multipass Cyclic Ion Mobility Spectrometry with an enhanced suite of fragmentation, probing, and imaging capabilities, the Waters Cyclic IMS P20 Mass Spectrometer reveals subtle biological differences for earlier, previously unattainable detection of disease signals." /> </a> </p> </div> <p>"Waters recognizes that advanced tools for structural and spatial omics play a critical role in delivering therapeutic breakthroughs," said James Hallam, Vice President & General Manager, Liquid Chromatography-Mass Spectrometry, Waters Analytical Sciences, Waters Corporation. "With its powerful fusion of capabilities, the Cyclic IMS P20 MS delivers a previously unattainable view into subtle molecular differences, unlocking a new level of understanding of the mechanisms that drive disease and advancing next‑generation discovery."</p><p>As researchers pursue larger and more heterogeneous therapeutic targets, analytical workflows need higher sensitivity, higher structural resolution, and easier-to-adopt methods

<span> <style> //<![CDATA[ .q4default span.prnews_span { font-size: 8pt; font-family: "Arial"; color: rgb(0, 0, 0) } .q4default a.prnews_a { color: rgb(0, 0, 255) } .q4default li.prnews_li { font-size: 8pt; font-family: "Arial"; color: rgb(0, 0, 0) } .q4default p.prnews_p { font-size: 0.62em; font-family: "Arial"; color: rgb(0, 0, 0); margin: 0 } //]]>// </style> <div class="q4default"> <div class="xn-content"> <ul type="disc"> <li>Delivers up to 20x improvement in MS/MS sensitivity and 2x faster acquisition speeds, enabling deeper biological insight for next-generation multiomics, therapeutic, and high-throughput workflows.</li> </ul> <ul type="disc"> <li>Identifies up to 40% more lipids by LC‑MS/MS than the leading alternative benchtop high‑resolution mass spectrometer, advancing lipidomics research and disease understanding.</li> </ul> <ul type="disc"> <li>Sets a new benchmark for throughput in high-resolution spatial analysis with the DESI XS source, supporting higher-confidence studies of disease and treatment response.</li> </ul> <p><span class="legendSpanClass">MILFORD, Mass.</span>, <span class="legendSpanClass">June 1, 2026</span> /PRNewswire/ -- 74^th&nbsp;ASMS Conference on Mass Spectrometry and Allied Topics&mdash;Waters Corporation (NYSE: WAT) today introduced the <a href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4700508-1&h=326936681&u=https%3A%2F%2Fwww.waters.com%2Fnextgen%2Fus%2Fen%2Fproducts%2Fmass-spectrometry%2Fmass-spectrometry-systems%2FXevoMRTP10.html%3Fcontp-npd_35486&a=Waters+Xevo%E2%84%A2+MRT+P10+Mass+Spectrometer" target="_blank" rel="nofollow noopener">Waters Xevo&trade; MRT P10 Mass Spectrometer</a>, a high-resolution Quadrupole Time-of-Flight (QToF) System for high-throughput multiomics, bioanalysis, and biopharmaceutical laboratories. The Xevo MRT P10 MS delivers up to 20x higher MS/MS sensitivity compared to its predecessor, along with industry-leading speed and expanded acquisition modes to comprehensively support both targeted and untargeted analysis in a single benchtop platform. The system is designed to accelerate biomarker discovery and validation while supporting the identification of disease pathways and therapeutic targets across large-cohort biomedical research and epidemiology studies.</p> <div id="DivAssetPlaceHolder1" class="PRN_ImbeddedAssetReference"> <p><a href="https://mma.prnewswire.com/media/2991645/Waters_Xevo_MRT_P10_MS.html" target="_blank" rel="nofollow noopener"> <img title="Waters Xevo&trade; MRT P10 MS introduces unrivaled sensitivity and speed to benchtop HRMS, enabling deeper biological insight for next-generation multiomics, therapeutic, and high-throughput workflows." src="https://mma.prnewswire.com/media/2991645/Waters_Xevo_MRT_P10_MS.jpg" alt="Waters Xevo&trade; MRT P10 MS introduces unrivaled sensitivity and speed to benchtop HRMS, enabling deeper biological insight for next-generation multiomics, therapeutic, and high-throughput workflows." /> </a></p> </div> <p>"With the Xevo MRT P10 MS, we are raising the standard for benchtop high-resolution mass spectrometry," said James Hallam, Vice President & General Manager, Liquid Chromatography-Mass Spectrometry, Waters Analytical Sciences, Waters Corporation. "By combining enhanced MS/MS sensitivity, the industry's fastest benchtop acquisition speeds, and advanced intelligent acquisition modes in LC-MS/MS &ndash; and layering in a new benchmark for MS imaging speed and throughput with our DESI XS &ndash; this platform empowers researchers to see more biology, accelerate discovery, and make confident decisions. The Xevo MRT P10 MS represents a powerful step forward for our customers working to advance multiomics research and life‑changing therapies."</p> <p>As researchers pursue deeper analytical insights, they face a bottleneck: generating high quality MS/MS information at the speed required by modern workflows. The Xevo MRT P10 MS is engineered to solve that problem. It offers up to 20&times; gre

<span> <style type="text/css"> //<![CDATA[ .q4default span.prnews_span { font-size: 8pt; font-family: "Arial"; color: rgb(0, 0, 0) } .q4default a.prnews_a { color: rgb(0, 0, 255) } .q4default li.prnews_li { font-size: 8pt; font-family: "Arial"; color: rgb(0, 0, 0) } .q4default p.prnews_p { font-size: 0.62em; font-family: "Arial"; color: rgb(0, 0, 0); margin: 0 } //]]>// </style> <div class="q4default"> <div class="xn-content"> <p><span class="legendSpanClass">MILFORD, Mass.</span>, <span class="legendSpanClass">May 18, 2026</span> /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3rd, 2026, at 10:30 AM Eastern Time.</p> <p>A live webcast of the event will be available on the 'Events & Presentations' section of Waters Investor Relations website at <a href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4690972-1&h=3862878262&u=https%3A%2F%2Fir.waters.com&a=https%3A%2F%2Fir.waters.com" target="_blank" rel="nofollow">https://ir.waters.com</a>. A replay of the webcast will be available for 90 days.</p><p><u>About Waters Corporation</u></p><p>Waters Corporation (NYSE:WAT) is a global leader in life sciences, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and service. With a focus on regulated, high-volume testing environments, our innovative portfolio harnesses deep scientific expertise across chemistry, physics, and biology. We collaborate with analytical laboratories around the world to advance the release of effective, high-quality medicines, assure the safety of food and water, and drive better patient outcomes by detecting diseases earlier, managing routine infections, and combatting growing antibiotic resistance. Through a shared culture of relentless innovation, our passionate team of approximately 16,000 employees partner with our customers to turn scientific challenges into breakthroughs that improve lives worldwide.</p><p>Caspar Tudor, Head of Investor Relations<br /><a href="mailto:investor_relations@waters.com" target="_blank" rel="nofollow">investor_relations@waters.com</a></p> <p id="PURL"><img title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=NY61977&sd=2026-05-18" /> View original content:<a id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/waters-corporation-to-present-at-the-jefferies-global-healthcare-conference-302775033.html" target="_blank">https://www.prnewswire.com/news-releases/waters-corporation-to-present-at-the-jefferies-global-healthcare-conference-302775033.html</a></p><p>SOURCE Waters Corporation</p></div> </div> </span>

<span> <style type="text/css"> //<![CDATA[ .q4default span.prnews_span { font-size: 8pt; font-family: "Arial"; color: rgb(0, 0, 0) } .q4default a.prnews_a { color: rgb(0, 0, 255) } .q4default li.prnews_li { font-size: 8pt; font-family: "Arial"; color: rgb(0, 0, 0) } .q4default p.prnews_p { font-size: 0.62em; font-family: "Arial"; color: rgb(0, 0, 0); margin: 0 } .q4default .prngen6 { padding-right: 0.17em; padding-left: 1.17em; vertical-align: bottom; text-align: left; border: 1pt rgb(0, 0, 0) } .q4default .prngen8 { padding-right: 0.17em; padding-left: 2.5em; vertical-align: bottom; text-align: left; border: 1pt rgb(0, 0, 0) } .q4default .prngen13 { padding-right: 0.83em; padding-left: 0.17em; vertical-align: bottom; text-align: right; border: 1pt rgb(0, 0, 0) } .q4default .prngen21 { padding-right: 0.5em; padding-left: 0.17em; vertical-align: bottom; text-align: right; border: 1pt rgb(0, 0, 0) } .q4default .prngen16 { padding-right: 0.83em; padding-left: 0.17em; vertical-align: bottom; text-align: right; border-width: 1pt 1pt 0.5pt; border-top-style: initial; border-color: rgb(0, 0, 0); border-right-style: initial; border-bottom-style: solid; border-left-style: initial } .q4default .prngen9 { padding-right: 0.17em; padding-left: 0.17em; vertical-align: bottom; text-align: right; border: 1pt rgb(0, 0, 0) } .q4default .prngen12 { padding-right: 0.17em; padding-left: 0.17em; vertical-align: bottom; text-align: justify; border: 1pt rgb(0, 0, 0) } .q4default .prngen3 { padding-right: 0.33em; padding-left: 0.17em; vertical-align: bottom; text-align: right; border: 1pt rgb(0, 0, 0) } .q4default .prngen27 { padding-right: 0.17em; padding-left: 0.17em; vertical-align: top; text-align: justify; border: 1pt rgb(0, 0, 0) } .q4default .prngen5 { padding-right: 0.17em; padding-left: 0.17em; vertical-align: bottom; text-align: left; border: 1pt rgb(0, 0, 0) } .q4default .prngen2 { padding-right: 0.17em; padding-left: 0.17em; vertical-align: bottom; text-align: center; border: 1pt rgb(0, 0, 0) } .q4default .prngen19 { padding-right: 0.17em; padding-left: 0.17em; vertical-align: top; text-align: center; border: 1pt rgb(0, 0, 0) } .q4default .prngen26 { padding-right: 0.17em; padding-left: 0.17em; vertical-align: top; text-align: right; border: 1pt rgb(0, 0, 0) } .q4default .prngen11 { padding-right: 0.17em; padding-left: 0.17em; vertical-align: bottom; text-align: right; border-width: 1pt 1pt 0.5pt; border-top-style: initial; border-color: rgb(0, 0, 0); border-right-style: initial; border-bottom-style: solid; border-left-style: initial } .q4default .prngen24 { padding-right: 0.5em; padding-left: 0.17em; vertical-align: bottom; text-align: right; border-width: 1pt 1pt 0.5pt; border-top-style: initial; border-color: rgb(0, 0, 0); border-right-style: initial; border-bottom-style: solid; border-left-style: initial } .q4default .prngen29 { padding-right: 0.17em; padding-left: 0.17em; vertical-align: bottom; text-align: right; border-width: 0.5pt 1pt 1pt; border-top-style: solid; border-color: rgb(0, 0, 0); border-right-style: initial; border-bottom-style: initial; border-left-style: initial } .q4default .prngen25 { padding-right: 0.17em; padding-left: 0.17em; vertical-align: top; text-align: right; border-width: 1pt 1pt 0.5pt; border-top-style: initial; border-color: rgb(0, 0, 0); border-right-style: initial; border-bottom-style: solid; border-left-style: initial } .q4default .prngen4 { padding-right: 0.17em; padding-left: 0.17em; vertical-align: bottom; text-align: center; border-width: 1pt 1pt 0.5pt; border-top-style: initial; border-color: rgb(0, 0, 0); border-right-style: initial; border-bottom-style: solid; border-left-style: initial } .q4default .prngen15 { padding-right: 0.83em; padding-left: 0.17em; vertical-align: bottom; text-align: right; border-top: 0.5pt solid rgb(0, 0, 0); border-right: 1pt rgb(0, 0, 0); BORDER-BOTTOM: black 3PT double; border-left: 1pt rgb(0, 0, 0) } .q4default .prngen7 { padding-right: 0.

<span> <style type="text/css"> //<![CDATA[ .q4default span.prnews_span { font-size: 8pt; font-family: "Arial"; color: rgb(0, 0, 0) } .q4default a.prnews_a { color: rgb(0, 0, 255) } .q4default li.prnews_li { font-size: 8pt; font-family: "Arial"; color: rgb(0, 0, 0) } .q4default p.prnews_p { font-size: 0.62em; font-family: "Arial"; color: rgb(0, 0, 0); margin: 0 } //]]>// </style> <div class="q4default"> <div class="xn-content"> <p><span class="legendSpanClass">MILFORD, Mass.</span>, <span class="legendSpanClass">April 20, 2026</span> /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q1 2026 financial results conference call on Tuesday, May 5, 2026 at 8:30 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at <a href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4668448-1&h=2767874946&u=https%3A%2F%2Fir.waters.com%2F&a=https%3A%2F%2Fir.waters.com" target="_blank" aria-invalid="true" rel="nofollow">https://ir.waters.com</a>. A replay of the webcast will also be available until at least June 2, 2026, at midnight Eastern Time.</p> <p><u>About Waters Corporation</u></p><p>Waters Corporation (NYSE: WAT) is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and service. With a focus on regulated, high-volume testing environments, our innovative portfolio harnesses deep scientific expertise across chemistry, physics, and biology. We collaborate with customers around the world to advance the release of effective, high-quality medicines, ensure the safety of food and water, and drive better patient outcomes by detecting diseases earlier, managing routine infections, and combating antibiotic resistance. Through a shared culture of relentless innovation, our passionate team of ~16,000 colleagues turn scientific challenges into breakthroughs that improve lives worldwide. For more information, please visit <a href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4668448-1&h=4290914313&u=http%3A%2F%2Fwww.waters.com%2Fabout&a=www.waters.com%2Fabout" target="_blank" rel="nofollow">www.waters.com/about</a>.</p><p>Caspar Tudor, Head of Investor Relations<br /><a href="mailto:investor_relations@waters.com" target="_blank" rel="nofollow">investor_relations@waters.com</a></p> <p id="PURL"><img title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=NY38568&sd=2026-04-20" /> View original content:<a id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/waters-corporation-schedules-first-quarter-2026-earnings-conference-call-302747613.html" target="_blank">https://www.prnewswire.com/news-releases/waters-corporation-schedules-first-quarter-2026-earnings-conference-call-302747613.html</a></p><p>SOURCE Waters Corporation</p></div> </div> </span>

<span> <style type="text/css"> //<![CDATA[ .q4default span.prnews_span { font-size: 8pt; font-family: "Arial"; color: rgb(0, 0, 0) } .q4default a.prnews_a { color: rgb(0, 0, 255) } .q4default li.prnews_li { font-size: 8pt; font-family: "Arial"; color: rgb(0, 0, 0) } .q4default p.prnews_p { font-size: 0.62em; font-family: "Arial"; color: rgb(0, 0, 0); margin: 0 } //]]>// </style> <div class="q4default"> <div class="xn-content"> <ul type="disc"><li>Delivers up to 4x faster chromatographic run times to accelerate decisions across discovery, development, and quality workflows.^1,3</li><li>Achieves 10x improvement in absolute molar mass and extended sizing, without compromising resolution or analytical throughput.²</li><li>Reduces sample consumption by 30-50% and solvent use by approximately 40%.³</li></ul><p><span class="legendSpanClass">MILFORD, Mass.</span>, <span class="legendSpanClass">April 14, 2026</span> /PRNewswire/ -- Waters Corporation (NYSE: WAT) today announced the launch of the Waters omniDAWN™ Multi-Angle Light Scattering (MALS) Photometer, part of the Wyatt Technology Portfolio. Featuring 18 angles of detection, the omniDAWN Photometer is the first extended-range MALS detector for Ultra High Performance Liquid Chromatography (UHPLC) and Ultra Performance Liquid Chromatography (UPLC) workflows, delivering absolute molar mass and size measurements without compromising resolution or throughput.</p><div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder2072"><p><a href="https://mma.prnewswire.com/media/2955292/omniDAWN_Hero_Image.html" target="_blank" rel="nofollow"><img src="https://mma.prnewswire.com/media/2955292/omniDAWN_Hero_Image.jpg" title="The omniDAWN MALS Photometer extends UPLC-compatible sizing ten-fold, enabling reliable characterization of more complex analytes including large molecules and advanced materials." alt="The omniDAWN MALS Photometer extends UPLC-compatible sizing ten-fold, enabling reliable characterization of more complex analytes including large molecules and advanced materials." /></a></p></div><p>The omniDAWN MALS Photometer extends UPLC-compatible sizing ten-fold, from approximately 50 to 500 nm in radius, enabling reliable characterization of larger, more complex analytes such as protein aggregates, viral vectors, lipid nanoparticles (LNPs), and advanced materials. Because it provides absolute molar mass and size, the omniDAWN Photometer reduces reliance on column calibration standards and supports faster results and more confident comparisons, streamlining work across biosimilarity studies, antibody-drug conjugate (ADC) characterization, and viral vector analytics. As these modalities and other advanced therapeutics move into late-stage development and quality control, laboratories increasingly rely on UHPLC and UPLC Systems to meet rising throughput and resolution requirements.</p><p>"Advances in UHPLC and UPLC separations for complex biologics and newer modalities have outpaced detector technology, until now," said Rob Carpio, Senior Vice President, Waters Analytical Sciences, Waters Corporation. "The omniDAWN MALS Photometer brings extended-range multi-angle light scattering to modern separations. This means our customers can move faster while maintaining the resolution, robustness, and depth of characterization needed to accelerate the discovery, development, and quality control of next-generation therapies."</p><p>Integrating seamlessly with Waters UPLC Systems and columns, the omniDAWN Photometer eliminates traditional trade-offs between dispersion, robustness, and analytical performance, delivering a complete solution for multi-attribute characterization with improved usability² compared to micro‑volume MALS approaches. When paired with UHPLC or UPLC Systems, the omniDAWN Photometer supports run times up to four times faster than conventional HPLC workflows, while reducing sample consumption by 30–50% and solvent use b